Kathrin H. Kirsch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kathrin H. Kirsch has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- Philip C. Trackman
The Forsyth Institute, 245 First Street, Cambridge, MA 02142, USA
14 shared publications Joerg Kumbrink
Department of Biochemistry, Boston University School of Medicine, 72 E. Concord Street, Boston, MA, 02118, USA
8 shared publicationsGail E. Sonenshein
Department of Biochemistry, Tufts University School of Medicine, Boston, Massachusetts, United States of America
6 shared publicationsYingshe Zhao
Department of Biochemistry, Boston University School of Medicine, Boston, Massachusetts, United States of America
6 shared publicationsChengyin Min
Department of Biochemistry, Boston University School of Medicine, 72 E. Concord St., Boston, Massachusetts 02118, USA
5 shared publications- Gail E. Sonenshein
Department of Biochemistry, Tufts University School of Medicine, Boston, Massachusetts, United States of America
5 shared publications
Latest Publications
- Open Access
- 12 May 2023
- Published by Walter de Gruyter GmbH in Oud Holland – Journal for Art of the Low Countries
- Vol. 136 (1) , 17-48
Cornelis Tromp’s trophies: The origins of a late portrait (1675-1676) by Ferdinand Bol
In 2018, Het Scheepvaartmuseum in Amsterdam acquired a portrait of Lieutenant-Admiral Cornelis Tromp (1629-1691), painted by Ferdinand Bol, from a private collection. Previously, this work was only known from a reproduction print by Lambert Visscher. After its acquisition, the portrait was restored in 2019, which is when its material and (art) historical aspects were examined. In the portrait, Tromp wears two insignia: a diamond portrait medallion on a red ribbon and the badge of the Danish Order of the Elephant. This badge was added to the portrait later, but by Bol himself. Tromp was thus initially depicted wearing only one of the insignia: the diamond medallion with the red ribbon. That Bol regarded this version of the portrait as completed is evidenced by the egg-white varnish he applied to it. At a later stage however, he exchanged this insignia for the badge of the Order of the Elephant. He carefully hid the medallion and ribbon from view by first scraping off their paint and then obscuring the remains of these forms with a layer of grey paint. Finally, he added the insignia of the Order of the Elephant. During a later restoration, the paint Bol used to cover the medallion and ribbon was largely removed, revealing these forms once again. The ship in the background is the Gouden Leeuw (Golden Lion), Tromp’s flagship during the Third Anglo-Dutch War (1672-1674). Since Tromp had received the portrait medallion from the English king in January 1675, the first portrait version can be dated to February 1675 at the earliest and May 1676 at the latest, when Tromp was appointed commander-in-chief of the Danish fleet in Denmark. After Tromp was elevated to the Order of the Elephant upon his arrival in Copenhagen, Bol altered the portrait to keep it in step with Tromp’s career. This chronology sheds new light on Bol’s artistic practice. which was always assumed to have ended in 1669 when Bol married the wealthy widow Anna van Erckel. However, Tromp’s portrait demonstrates that Bol continued to paint into the second half of the 1670s. After his elevation to the Order of the Elephant, Tromp only allowed himself to be portrayed with this insignia, which was always depicted correctly. It was only Bol who depicted the badge incorrectly, indicating that he did not make the adjustment at Tromp’s instigation. Presumably Bol did this of his own initiative, or that of his wife’s, Anna van Erckel. Archival evidence strongly suggests that she was the first owner of the portrait and that she also owned a portrait, painted by Bol, of Tromp’s wife Margaretha van Raephorst. It was not previously known that Bol had painted her, however a portrait by him of an anonymous woman is clearly Van Raephorst’s likeness. Archival documents show that Van Erckel and Bol knew the Tromp couple personally and maintained friendly relations with them. In Bol and Van Erckel’s stately canal house, the portraits would have been ‘proof’ of that personal relationship.
- 12 May 2023
- Published by Walter de Gruyter GmbH in Oud Holland – Journal for Art of the Low Countries
- Vol. 136 (1) , 17-48
Open AccessCornelis Tromp’s trophies: The origins of a late portrait (1675-1676) by Ferdinand Bol
In 2018, Het Scheepvaartmuseum in Amsterdam acquired a portrait of Lieutenant-Admiral Cornelis Tromp (1629-1691), painted by Ferdinand Bol, from a private collection. Previously, this work was only known from a reproduction print by Lambert Visscher. After its acquisition, the portrait was restored in 2019, which is when its material and (art) historical aspects were examined. In the portrait, Tromp wears two insignia: a diamond portrait medallion on a red ribbon and the badge of the Danish Order of the Elephant. This badge was added to the portrait later, but by Bol himself. Tromp was thus initially depicted wearing only one of the insignia: the diamond medallion with the red ribbon. That Bol regarded this version of the portrait as completed is evidenced by the egg-white varnish he applied to it. At a later stage however, he exchanged this insignia for the badge of the Order of the Elephant. He carefully hid the medallion and ribbon from view by first scraping off their paint and then obscuring the remains of these forms with a layer of grey paint. Finally, he added the insignia of the Order of the Elephant. During a later restoration, the paint Bol used to cover the medallion and ribbon was largely removed, revealing these forms once again. The ship in the background is the Gouden Leeuw (Golden Lion), Tromp’s flagship during the Third Anglo-Dutch War (1672-1674). Since Tromp had received the portrait medallion from the English king in January 1675, the first portrait version can be dated to February 1675 at the earliest and May 1676 at the latest, when Tromp was appointed commander-in-chief of the Danish fleet in Denmark. After Tromp was elevated to the Order of the Elephant upon his arrival in Copenhagen, Bol altered the portrait to keep it in step with Tromp’s career. This chronology sheds new light on Bol’s artistic practice. which was always assumed to have ended in 1669 when Bol married the wealthy widow Anna van Erckel. However, Tromp’s portrait demonstrates that Bol continued to paint into the second half of the 1670s. After his elevation to the Order of the Elephant, Tromp only allowed himself to be portrayed with this insignia, which was always depicted correctly. It was only Bol who depicted the badge incorrectly, indicating that he did not make the adjustment at Tromp’s instigation. Presumably Bol did this of his own initiative, or that of his wife’s, Anna van Erckel. Archival evidence strongly suggests that she was the first owner of the portrait and that she also owned a portrait, painted by Bol, of Tromp’s wife Margaretha van Raephorst. It was not previously known that Bol had painted her, however a portrait by him of an anonymous woman is clearly Van Raephorst’s likeness. Archival documents show that Van Erckel and Bol knew the Tromp couple personally and maintained friendly relations with them. In Bol and Van Erckel’s stately canal house, the portraits would have been ‘proof’ of that personal relationship.
- Open Access
- 1 December 2020
- Published by Springer Nature in The EMBO Journal
- Vol. 40 (2) , e105926
Multiplexed CRISPR/CAS9‐mediated engineering of pre‐clinical mouse models bearing native human B cell receptors
B‐cell receptor (BCR) knock‐in (KI) mouse models play an important role in vaccine development and fundamental immunological studies. However, the time required to generate them poses a bottleneck. Here we report a one‐step CRISPR/Cas9 KI methodology to combine the insertion of human germline immunoglobulin heavy and light chains at their endogenous loci in mice. We validate this technology with the rapid generation of three BCR KI lines expressing native human precursors, instead of computationally inferred germline sequences, to HIV broadly neutralizing antibodies. We demonstrate that B cells from these mice are fully functional: upon transfer to congenic, wild type mice at controlled frequencies, such B cells can be primed by eOD‐GT8 60mer, a germline‐targeting immunogen currently in clinical trials, recruited to germinal centers, secrete class‐switched antibodies, undergo somatic hypermutation, and differentiate into memory B cells. KI mice expressing functional human BCRs promise to accelerate the development of vaccines for HIV and other infectious diseases.
- 1 December 2020
- Published by Springer Nature in The EMBO Journal
- Vol. 40 (2) , e105926
Open AccessMultiplexed CRISPR/CAS9‐mediated engineering of pre‐clinical mouse models bearing native human B cell receptors
B‐cell receptor (BCR) knock‐in (KI) mouse models play an important role in vaccine development and fundamental immunological studies. However, the time required to generate them poses a bottleneck. Here we report a one‐step CRISPR/Cas9 KI methodology to combine the insertion of human germline immunoglobulin heavy and light chains at their endogenous loci in mice. We validate this technology with the rapid generation of three BCR KI lines expressing native human precursors, instead of computationally inferred germline sequences, to HIV broadly neutralizing antibodies. We demonstrate that B cells from these mice are fully functional: upon transfer to congenic, wild type mice at controlled frequencies, such B cells can be primed by eOD‐GT8 60mer, a germline‐targeting immunogen currently in clinical trials, recruited to germinal centers, secrete class‐switched antibodies, undergo somatic hypermutation, and differentiate into memory B cells. KI mice expressing functional human BCRs promise to accelerate the development of vaccines for HIV and other infectious diseases.
- 22 March 2018
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 39 (7) , 921-930
A polymorphism in the lysyl oxidase propeptide domain accelerates carcinogen-induced cancer
The propeptide (LOX-PP) domain of the lysyl oxidase proenzyme was shown to inhibit the transformed phenotype of breast, lung and pancreatic cells in culture and the formation of Her2/neu-driven breast cancer in a xenograft model. A single nucleotide polymorphism (SNP, rs1800449) positioned in a highly conserved region of LOX-PP results in an Arg158Gln substitution (humans). This arginine (Arg)→glutamine (Gln) substitution profoundly impaired the ability of LOX-PP to inhibit the invasive phenotype and xenograft tumor formation. To study the effect of the SNP in vivo, here we established a knock in (KI) mouse line (LOX-PPGln mice) expressing an Arg152Gln substitution corresponding to the human Arg158Gln polymorphism. Breast cancer was induced in wild-type (WT) and LOX-PPGln female mice beginning at 6 weeks of age by treatment with 7,12-dimethylbenz(a)anthracene (DMBA) in combination with progesterone. Time course analysis of tumor development demonstrated earlier tumor onset and shorter overall survival in LOX-PPGln versus WT mice. To further compare the tumor burden in WT and LOX-PPGln mice, inguinal mammary glands from both groups of mice were examined for microscopic lesion formation. LOX-PPGln glands contained more lesions (9.6 versus 6.9 lesions/#4 bilateral). In addition, more DMBA-treated LOX-PPGln mice had increased leukocyte infiltrations in their livers and were moribund compared with DMBA-treated WT mice. Thus, these data indicate that the Arg→Gln substitution in LOX-PP could be an important marker associated with a more aggressive cancer phenotype and that this KI model is ideal for further mechanistic studies regarding the tumor suppressor function of LOX-PP.
- 22 March 2018
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 39 (7) , 921-930
A polymorphism in the lysyl oxidase propeptide domain accelerates carcinogen-induced cancer
The propeptide (LOX-PP) domain of the lysyl oxidase proenzyme was shown to inhibit the transformed phenotype of breast, lung and pancreatic cells in culture and the formation of Her2/neu-driven breast cancer in a xenograft model. A single nucleotide polymorphism (SNP, rs1800449) positioned in a highly conserved region of LOX-PP results in an Arg158Gln substitution (humans). This arginine (Arg)→glutamine (Gln) substitution profoundly impaired the ability of LOX-PP to inhibit the invasive phenotype and xenograft tumor formation. To study the effect of the SNP in vivo, here we established a knock in (KI) mouse line (LOX-PPGln mice) expressing an Arg152Gln substitution corresponding to the human Arg158Gln polymorphism. Breast cancer was induced in wild-type (WT) and LOX-PPGln female mice beginning at 6 weeks of age by treatment with 7,12-dimethylbenz(a)anthracene (DMBA) in combination with progesterone. Time course analysis of tumor development demonstrated earlier tumor onset and shorter overall survival in LOX-PPGln versus WT mice. To further compare the tumor burden in WT and LOX-PPGln mice, inguinal mammary glands from both groups of mice were examined for microscopic lesion formation. LOX-PPGln glands contained more lesions (9.6 versus 6.9 lesions/#4 bilateral). In addition, more DMBA-treated LOX-PPGln mice had increased leukocyte infiltrations in their livers and were moribund compared with DMBA-treated WT mice. Thus, these data indicate that the Arg→Gln substitution in LOX-PP could be an important marker associated with a more aggressive cancer phenotype and that this KI model is ideal for further mechanistic studies regarding the tumor suppressor function of LOX-PP.
- 20 January 2017
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 118 (8) , 2347-2356
UXT Is a LOX-PP Interacting Protein That Modulates Estrogen Receptor Alpha Activity in Breast Cancer Cells
The lysyl oxidase proenzyme propeptide region (LOX-PP) is a tumor suppressor protein whose mechanism of action is not completely understood. Here, the Ubiquitously expressed Transcript (UXT) was identified in a yeast two-hybrid assay with LOX-PP as bait and confirmed as a novel LOX-PP associating protein. UXT, a prefoldin-like protein, is ubiquitous in human and mouse. Since UXT modulates androgen receptor transcriptional activity in prostate cancer, we studied its role in breast cancer. Breast tumors and derived cell lines overexpressed UXT. UXT was able to associate with the estrogen receptor alpha (ER) and decrease its transcriptional activity and target gene expression. Conversely, UXT knockdown increased ER element-dependent transcriptional activity. Ectopic LOX-PP relocalized UXT to the cytoplasm and decreased its stability. UXT ubiquitination and depletion in the presence of LOX-PP was rescued by a proteasomal inhibitor. In summary, proteasome-mediated turnover of UXT upon interaction with LOX-PP releases repression of ER transcriptional activity. J. Cell. Biochem. 118: 2347–2356, 2017.
- 20 January 2017
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 118 (8) , 2347-2356
UXT Is a LOX-PP Interacting Protein That Modulates Estrogen Receptor Alpha Activity in Breast Cancer Cells
The lysyl oxidase proenzyme propeptide region (LOX-PP) is a tumor suppressor protein whose mechanism of action is not completely understood. Here, the Ubiquitously expressed Transcript (UXT) was identified in a yeast two-hybrid assay with LOX-PP as bait and confirmed as a novel LOX-PP associating protein. UXT, a prefoldin-like protein, is ubiquitous in human and mouse. Since UXT modulates androgen receptor transcriptional activity in prostate cancer, we studied its role in breast cancer. Breast tumors and derived cell lines overexpressed UXT. UXT was able to associate with the estrogen receptor alpha (ER) and decrease its transcriptional activity and target gene expression. Conversely, UXT knockdown increased ER element-dependent transcriptional activity. Ectopic LOX-PP relocalized UXT to the cytoplasm and decreased its stability. UXT ubiquitination and depletion in the presence of LOX-PP was rescued by a proteasomal inhibitor. In summary, proteasome-mediated turnover of UXT upon interaction with LOX-PP releases repression of ER transcriptional activity. J. Cell. Biochem. 118: 2347–2356, 2017.
- 11 February 2016
- Published by Springer Nature in Tumor Biology
- Vol. 37 (8) , 10665-10673
A truncated phosphorylated p130Cas substrate domain is sufficient to drive breast cancer growth and metastasis formation in vivo
Elevated p130Cas (Crk-associated substrate) levels are found in aggressive breast tumors and are associated with poor prognosis and resistance to standard therapeutics in patients. p130Cas signals majorly through its phosphorylated substrate domain (SD) that contains 15 tyrosine motifs (YxxP) which recruit effector molecules. Tyrosine phosphorylation of p130Cas is important for mediating migration, invasion, tumor promotion, and metastasis. We previously developed a Src*/SD fusion molecule approach, where the SD is constitutively phosphorylated. In a polyoma middle T-antigen (PyMT)/Src*/SD double-transgenic mouse model, Src*/SD accelerates PyMT-induced tumor growth and promotes a more aggressive phenotype. To test whether Src*/SD also drives metastasis and which of the YxxP motifs are involved in this process, full-length and truncated SD molecules fused to Src* were expressed in breast cancer cells. The functionality of the Src*/SD fragments was analyzed in vitro, and the active proteins were tested in vivo in an orthotopic mouse model. Breast cancer cells expressing the full-length SD and the functional smaller SD fragment (spanning SD motifs 6–10) were injected into the mammary fat pads of mice. The tumor progression was monitored by bioluminescence imaging and caliper measurements. Compared with control animals, the complete SD promoted primary tumor growth and an earlier onset of metastases. Importantly, both the complete and truncated SD significantly increased the occurrence of metastases to multiple organs. These studies provide strong evidence that the phosphorylated p130Cas SD motifs 6–10 (Y236, Y249, Y267, Y287, and Y306) are important for driving mammary carcinoma progression.
- 11 February 2016
- Published by Springer Nature in Tumor Biology
- Vol. 37 (8) , 10665-10673
A truncated phosphorylated p130Cas substrate domain is sufficient to drive breast cancer growth and metastasis formation in vivo
Elevated p130Cas (Crk-associated substrate) levels are found in aggressive breast tumors and are associated with poor prognosis and resistance to standard therapeutics in patients. p130Cas signals majorly through its phosphorylated substrate domain (SD) that contains 15 tyrosine motifs (YxxP) which recruit effector molecules. Tyrosine phosphorylation of p130Cas is important for mediating migration, invasion, tumor promotion, and metastasis. We previously developed a Src*/SD fusion molecule approach, where the SD is constitutively phosphorylated. In a polyoma middle T-antigen (PyMT)/Src*/SD double-transgenic mouse model, Src*/SD accelerates PyMT-induced tumor growth and promotes a more aggressive phenotype. To test whether Src*/SD also drives metastasis and which of the YxxP motifs are involved in this process, full-length and truncated SD molecules fused to Src* were expressed in breast cancer cells. The functionality of the Src*/SD fragments was analyzed in vitro, and the active proteins were tested in vivo in an orthotopic mouse model. Breast cancer cells expressing the full-length SD and the functional smaller SD fragment (spanning SD motifs 6–10) were injected into the mammary fat pads of mice. The tumor progression was monitored by bioluminescence imaging and caliper measurements. Compared with control animals, the complete SD promoted primary tumor growth and an earlier onset of metastases. Importantly, both the complete and truncated SD significantly increased the occurrence of metastases to multiple organs. These studies provide strong evidence that the phosphorylated p130Cas SD motifs 6–10 (Y236, Y249, Y267, Y287, and Y306) are important for driving mammary carcinoma progression.
- Open Access
- 1 October 2015
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 290 (42) , 25275-25292
Differential Recognition Preferences of the Three Src Homology 3 (SH3) Domains from the Adaptor CD2-associated Protein (CD2AP) and Direct Association with Ras and Rab Interactor 3 (RIN3)
- 1 October 2015
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 290 (42) , 25275-25292
Open AccessDifferential Recognition Preferences of the Three Src Homology 3 (SH3) Domains from the Adaptor CD2-associated Protein (CD2AP) and Direct Association with Ras and Rab Interactor 3 (RIN3)
- Open Access
- 1 May 2015
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 290 (19) , 12247-12255
Identification of Novel Crk-associated Substrate (p130Cas) Variants with Functionally Distinct Focal Adhesion Kinase Binding Activities
- 1 May 2015
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 290 (19) , 12247-12255
Open AccessIdentification of Novel Crk-associated Substrate (p130Cas) Variants with Functionally Distinct Focal Adhesion Kinase Binding Activities
- Open Access
- 22 October 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (10) , e77288
Inhibition of CIN85-Mediated Invasion by a Novel SH3 Domain Binding Motif in the Lysyl Oxidase Propeptide
The lysyl oxidase gene inhibits Ras signaling in transformed fibroblasts and breast cancer cells. Its activity was mapped to the 162 amino acid propeptide domain (LOX-PP) of the lysyl oxidase precursor protein. LOX-PP inhibited the Her-2/Ras signaling axis in breast cancer cells, and reduced the Her-2-driven breast tumor burden in a xenograft model. Since its mechanism of action is largely unknown, co-affinity-purification/mass spectrometry was performed and the “Cbl-interacting protein of 85-kDa” (CIN85) identified as an associating protein. CIN85 is an SH3-containing adapter protein that is overexpressed in invasive breast cancers. The CIN85 SH3 domains interact with c-Cbl, an E3 ubiquitin ligase, via an unconventional PxxxPR ligand sequence, with the highest affinity displayed by the SH3-B domain. Interaction with CIN85 recruits c-Cbl to the AMAP1 complex where its ubiquitination activity is necessary for cancer cells to develop an invasive phenotype and to degrade the matrix. Direct interaction of LOX-PP with CIN85 was confirmed using co-immunoprecipitation analysis of lysates from breast cancer cells and of purified expressed proteins. CIN85 interaction with c-Cbl was reduced by LOX-PP. Domain specific CIN85 regions and deletion mutants of LOX-PP were prepared and used to map the sites of interaction to the SH3-B domain of CIN85 and to an epitope encompassing amino acids 111 to 116 of LOX-PP. Specific LOX-PP point mutant proteins P111A and R116A failed to interact with CIN85 or to compete for CIN85 binding with c-Cbl. Structural modeling identified a new atypical PxpxxRh SH3-binding motif in this region of LOX-PP. The LOX-PP interaction with CIN85 was shown to reduce the invasive phenotype of breast cancer cells, including their ability to degrade the surrounding extracellular matrix and for Matrigel outgrowth. Thus, LOX-PP interacts with CIN85 via a novel SH3-binding motif and this association reduces CIN85-promoted invasion by breast cancer cells.
- 22 October 2013
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (10) , e77288
Open AccessInhibition of CIN85-Mediated Invasion by a Novel SH3 Domain Binding Motif in the Lysyl Oxidase Propeptide
The lysyl oxidase gene inhibits Ras signaling in transformed fibroblasts and breast cancer cells. Its activity was mapped to the 162 amino acid propeptide domain (LOX-PP) of the lysyl oxidase precursor protein. LOX-PP inhibited the Her-2/Ras signaling axis in breast cancer cells, and reduced the Her-2-driven breast tumor burden in a xenograft model. Since its mechanism of action is largely unknown, co-affinity-purification/mass spectrometry was performed and the “Cbl-interacting protein of 85-kDa” (CIN85) identified as an associating protein. CIN85 is an SH3-containing adapter protein that is overexpressed in invasive breast cancers. The CIN85 SH3 domains interact with c-Cbl, an E3 ubiquitin ligase, via an unconventional PxxxPR ligand sequence, with the highest affinity displayed by the SH3-B domain. Interaction with CIN85 recruits c-Cbl to the AMAP1 complex where its ubiquitination activity is necessary for cancer cells to develop an invasive phenotype and to degrade the matrix. Direct interaction of LOX-PP with CIN85 was confirmed using co-immunoprecipitation analysis of lysates from breast cancer cells and of purified expressed proteins. CIN85 interaction with c-Cbl was reduced by LOX-PP. Domain specific CIN85 regions and deletion mutants of LOX-PP were prepared and used to map the sites of interaction to the SH3-B domain of CIN85 and to an epitope encompassing amino acids 111 to 116 of LOX-PP. Specific LOX-PP point mutant proteins P111A and R116A failed to interact with CIN85 or to compete for CIN85 binding with c-Cbl. Structural modeling identified a new atypical PxpxxRh SH3-binding motif in this region of LOX-PP. The LOX-PP interaction with CIN85 was shown to reduce the invasive phenotype of breast cancer cells, including their ability to degrade the surrounding extracellular matrix and for Matrigel outgrowth. Thus, LOX-PP interacts with CIN85 via a novel SH3-binding motif and this association reduces CIN85-promoted invasion by breast cancer cells.
- 1 September 2013
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 33 (18) , 3659-3666
Insulin Inhibits Lipolysis in Adipocytes via the Evolutionarily Conserved mTORC1-Egr1-ATGL-Mediated Pathway
One of the basic functions of insulin in the body is to inhibit lipolysis in adipocytes. Recently, we have found that insulin inhibits lipolysis and promotes triglyceride storage by decreasing transcription of adipose triglyceride lipase via the mTORC1-mediated pathway (P. Chakrabarti et al., Diabetes 59:775–781, 2010), although the mechanism of this effect remained unknown. Here, we used a genetic screen in Saccharomyces cerevisiae in order to identify a transcription factor that mediates the effect of Tor1 on the expression of the ATGL ortholog in yeast. This factor, Msn4p, has homologues in mammalian cells that form a family of early growth response transcription factors. One member of the family, Egr1, is induced by insulin and nutrients and directly inhibits activity of the ATGL promoter in vitro and expression of ATGL in cultured adipocytes. Feeding animals a high-fat diet increases the activity of mTORC1 and the expression of Egr1 while decreasing ATGL levels in epididymal fat. We suggest that the evolutionarily conserved mTORC1-Egr1-ATGL regulatory pathway represents an important component of the antilipolytic effect of insulin in the mammalian organism.
- 1 September 2013
- Published by Taylor & Francis in Molecular and Cellular Biology
- Vol. 33 (18) , 3659-3666
Insulin Inhibits Lipolysis in Adipocytes via the Evolutionarily Conserved mTORC1-Egr1-ATGL-Mediated Pathway
One of the basic functions of insulin in the body is to inhibit lipolysis in adipocytes. Recently, we have found that insulin inhibits lipolysis and promotes triglyceride storage by decreasing transcription of adipose triglyceride lipase via the mTORC1-mediated pathway (P. Chakrabarti et al., Diabetes 59:775–781, 2010), although the mechanism of this effect remained unknown. Here, we used a genetic screen in Saccharomyces cerevisiae in order to identify a transcription factor that mediates the effect of Tor1 on the expression of the ATGL ortholog in yeast. This factor, Msn4p, has homologues in mammalian cells that form a family of early growth response transcription factors. One member of the family, Egr1, is induced by insulin and nutrients and directly inhibits activity of the ATGL promoter in vitro and expression of ATGL in cultured adipocytes. Feeding animals a high-fat diet increases the activity of mTORC1 and the expression of Egr1 while decreasing ATGL levels in epididymal fat. We suggest that the evolutionarily conserved mTORC1-Egr1-ATGL regulatory pathway represents an important component of the antilipolytic effect of insulin in the mammalian organism.
- Open Access
- 23 August 2013
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 100 (3) , 461-471
Cysteine-rich protein 2 alters p130Cas localization and inhibits vascular smooth muscle cell migration
Cysteine-rich protein (CRP) 2, a member of the LIM-only CRP family that contains two LIM domains, is expressed in vascular smooth muscle cells (VSMCs) of blood vessels and functions to repress VSMC migration and vascular remodelling. The goal of this study was to define the molecular mechanisms by which CRP2 regulates VSMC migration. Transfection of VSMCs with CRP2-EGFP constructs revealed that CRP2 associated with the actin cytoskeleton. In response to chemoattractant stimulation, Csrp2 (mouse CRP2 gene symbol)-deficient (Csrp2−/−) VSMCs exhibited increased lamellipodia formation. Re-introduction of CRP2 abrogated the enhanced lamellipodia formation and migration of Csrp2−/− VSMCs following chemoattractant stimulation. Mammalian 2-hybrid and co-immunoprecipitation assays demonstrated that CRP2 interacts with p130Cas, a scaffold protein important for lamellipodia formation and cell motility. Immunofluorescence staining showed that CRP2 colocalized with phospho-p130Cas at focal adhesions (FAs)/terminal ends of stress fibres in non-migrating cells. Interestingly, in migrating cells phospho-p130Cas localized to the leading edge of lamellipodia and FAs, whereas CRP2 was restricted to FAs and stress fibres. Furthermore, we demonstrated that p130Cas expression and phosphorylation promote neointima formation following arterial injury. These studies demonstrate that CRP2 sequesters p130Cas at FAs, thereby reducing lamellipodia formation and blunting VSMC migration.
- 23 August 2013
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 100 (3) , 461-471
Open AccessCysteine-rich protein 2 alters p130Cas localization and inhibits vascular smooth muscle cell migration
Cysteine-rich protein (CRP) 2, a member of the LIM-only CRP family that contains two LIM domains, is expressed in vascular smooth muscle cells (VSMCs) of blood vessels and functions to repress VSMC migration and vascular remodelling. The goal of this study was to define the molecular mechanisms by which CRP2 regulates VSMC migration. Transfection of VSMCs with CRP2-EGFP constructs revealed that CRP2 associated with the actin cytoskeleton. In response to chemoattractant stimulation, Csrp2 (mouse CRP2 gene symbol)-deficient (Csrp2−/−) VSMCs exhibited increased lamellipodia formation. Re-introduction of CRP2 abrogated the enhanced lamellipodia formation and migration of Csrp2−/− VSMCs following chemoattractant stimulation. Mammalian 2-hybrid and co-immunoprecipitation assays demonstrated that CRP2 interacts with p130Cas, a scaffold protein important for lamellipodia formation and cell motility. Immunofluorescence staining showed that CRP2 colocalized with phospho-p130Cas at focal adhesions (FAs)/terminal ends of stress fibres in non-migrating cells. Interestingly, in migrating cells phospho-p130Cas localized to the leading edge of lamellipodia and FAs, whereas CRP2 was restricted to FAs and stress fibres. Furthermore, we demonstrated that p130Cas expression and phosphorylation promote neointima formation following arterial injury. These studies demonstrate that CRP2 sequesters p130Cas at FAs, thereby reducing lamellipodia formation and blunting VSMC migration.